Edition:
United States

OPKO Health Inc (OPK.O)

OPK.O on Nasdaq

2.12USD
2:33pm EDT
Change (% chg)

$0.05 (+2.16%)
Prev Close
$2.08
Open
$2.09
Day's High
$2.14
Day's Low
$2.08
Volume
1,338,172
Avg. Vol
4,549,325
52-wk High
$6.16
52-wk Low
$1.73

Latest Key Developments (Source: Significant Developments)

Opko Health Submits De Novo Request to FDA For The 4Kscore® Test
Thursday, 20 Jun 2019 08:00am EDT 

June 20 (Reuters) - OPKO Health Inc ::OPKO HEALTH SUBMITS DE NOVO REQUEST TO THE U.S. FDA FOR THE 4KSCORE® TEST.OPKO HEALTH INC - EXPECTS TO RECEIVE A RESPONSE TO REQUEST WITHIN APPROXIMATELY 180 DAYS.  Full Article

Opko Health Qtrly Loss Per Share $0.14
Tuesday, 7 May 2019 04:20pm EDT 

May 7 (Reuters) - OPKO Health Inc ::OPKO HEALTH REPORTS 2019 FIRST QUARTER BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS.Q1 REVENUE $222.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $241.3 MILLION.QTRLY LOSS PER SHARE $0.14.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $207.3 MILLION AS OF MARCH 31.  Full Article

Opko Health Inc Says Topline Analysis Of Results Of Study Demonstrated That OPK88003 Met Primary Objective
Thursday, 21 Mar 2019 08:02am EDT 

March 21 (Reuters) - OPKO Health Inc ::OPKO ANNOUNCES POSITIVE TOPLINE RESULTS IN PHASE 2 DIABETES AND OBESITY TRIAL.OPKO HEALTH INC - TOPLINE ANALYSIS OF RESULTS OF STUDY DEMONSTRATED THAT OPK88003 MET PRIMARY OBJECTIVE.OPKO HEALTH INC - STUDY ALSO SHOWED STATISTICALLY SIGNIFICANT LOWERING OF HEMOGLOBIN A1C (HBA1C) AFTER 30 WEEKS OF TREATMENT VERSUS PLACEBO.OPKO HEALTH INC - MOST FREQUENT ADVERSE EVENTS WERE NAUSEA, VOMITING AND DIARRHEA IN STUDY.OPKO HEALTH INC - NO SERIOUS ADVERSE EVENTS WERE OBSERVED IN STUDY.  Full Article

Opko Health Inc Announces Proposed Offering Of Convertible Senior Notes
Monday, 4 Feb 2019 04:20pm EST 

Feb 4 (Reuters) - OPKO Health Inc ::OPKO HEALTH INC ANNOUNCES PROPOSED OFFERING OF CONVERTIBLE SENIOR NOTES.OPKO HEALTH INC - INTENDS TO OFFER $200 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2025.OPKO HEALTH INC - NOTES WILL PAY INTEREST SEMIANNUALLY IN ARREARS.OPKO HEALTH INC - INTENDS TO USE NET PROCEEDS RECEIVED FROM OFFERING OF NOTES TO FUND RESEARCH AND DEVELOPMENT.  Full Article

OPKO Health And OPKO's CEO & Chairman, Dr. Phillip Frost, Announce Proposed Resolution Of SEC Action
Thursday, 27 Dec 2018 04:34pm EST 

Dec 27 (Reuters) - OPKO Health Inc ::OPKO HEALTH AND OPKO'S CEO AND CHAIRMAN, DR. PHILLIP FROST, ANNOUNCE PROPOSED RESOLUTION OF SEC ACTION.OPKO HEALTH INC - FROST WILL CONTINUE TO SERVE AS OPKO'S CEO AND CHAIRMAN..OPKO HEALTH INC - FROST TO CONTINUE AS CEO AND CHAIRMAN OF OPKO.OPKO HEALTH INC - FROST AGREED TO INJUNCTIONS FROM CERTAIN VIOLATIONS; ABOUT $5.5 MILLION IN PENALTY, DISGORGEMENT, AND PREJUDGMENT INTEREST.  Full Article

Opko Health Says Board Resolved To Voluntary Delist Common Stock From Tel Aviv Stock Exchange SEC Filing
Monday, 9 Apr 2018 04:38pm EDT 

April 9 (Reuters) - OPKO Health Inc ::OPKO HEALTH SAYS BOARD RESOLVED TO VOLUNTARY DELIST COMMON STOCK FROM TEL AVIV STOCK EXCHANGE - SEC FILING.  Full Article

OPKO Health Qtrly Diluted Loss Per Share $0.38
Thursday, 1 Mar 2018 04:05pm EST 

March 1 (Reuters) - OPKO Health Inc ::OPKO HEALTH REPORTS 2017 FOURTH QUARTER BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS.Q4 REVENUE $193.7 MILLION VERSUS $275.5 MILLION.QTRLY DILUTED LOSS PER SHARE $0.38.  Full Article

Opko Health qtrly loss per share $0.08‍​
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Opko Health Inc ::Opko Health reports 2017 third quarter highlights and financial results.Q3 revenue $263.5 million versus I/B/E/S view $319.4 million.Opko Health Inc qtrly loss per share $0.08‍​.  Full Article

OPKO Health submits premarket approval application with FDA for PSA test
Tuesday, 7 Nov 2017 08:00am EST 

Nov 7 (Reuters) - OPKO Health Inc :OPKO Health submits premarket approval application with FDA for a point-of-care PSA test with the Claros 1 platform.OPKO Health Inc - ‍filing contains clinical data from company's 864-patient total psa clinical study​.OPKO Health Inc - ‍OPKO expects to initiate clinical validation studies and to file a 510(k) application for a Claros 1 testosterone test in 2018​.OPKO Health - working to add additional tests for vitamin D, infectious diseases, cardiology, women's health, companion diagnostics to Claros 1 menu​.  Full Article

Xenetic Biosciences enters into sublicense agreement with subsidiary of Shire Plc
Thursday, 2 Nov 2017 08:05am EDT 

Nov 2 (Reuters) - Xenetic Biosciences :Xenetic Biosciences enters into sublicense agreement related to its Polyxen technology with Baxalta Inc., a wholly-owned subsidiary of Shire Plc.Xenetic Biosciences Inc - ‍Xenetic to receive one-time payment of $7.5 million and single digit royalty payments based upon net sales​.  Full Article

Opko Health says over 400,000 customers likely affected by data breach

Opko Health Inc said on Thursday it was notified by its former billing collections vendor about unauthorized access to information on about 422,600 customers, making it the third healthcare company to be affected by the incident.